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Abstract 
Purpose: To provide a robust, efficient synthesis of the malaria drug piperaquine for potential use in 
resource-poor settings.   
Methods: We used in-process analytical technologies (IPAT; HPLC) and a program of experiments to 
develop a synthesis of piperaquine that avoids the presence of a toxic impurity in the API and is 
optimized for overall yield and operational simplicity. 
Results : A green-chemical synthesis of piperaquine is described that proceeds in 92 – 93 % overall 
yield.  The chemistry is robust and provides very pure piperaquine tetraphosphate salt (> 99.5 %).  The 
overall process utilizes modest amounts (about 8 kg/kg) of 2-propanol and ethyl acetate as the only 
organic materials not incorporated into the API; roughly 60 % of this waste can be recycled into the 
production process.  This process also completely avoids the formation of a toxic impurity commonly 
seen in piperaquine that is otherwise difficult to remove. 
Conclusion: An efficient synthesis of piperaquine is described that may be useful for application in 
resource-poor settings as a means of expanding access to and reducing the cost of ACTs.   
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Piperaquine.  
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




A high level of global awareness has been 
generated of the mortality, morbidity and 
economic burden resulting from lack of essential 
medicines in resource-poor settings [1].  Several 
International Donor Agencies target increased 
access to essential medicines.  Artemisinin 
Combination Therapies (ACTs) are 
recommended by the World Health Organization 
for the treatment of uncomplicated malaria.  The 
combination of dihydroartemisinin + piperaquine  
(DHAP) has demonstrated superior efficacy and 
post-treatment prophylaxis against Plasmodial 
forms of malaria (Figure 1) [2].   Two major donor 
agencies, GFATM (the Global Fund for AIDS, 
Tuberculosis and Malaria) and PEPFAR (US 
President’s Emergency Plan for AIDS Relief), 
provide several billion USD each year for the 
management of HIV/AIDS, malaria, and other  
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neglected diseases [3]. The Affordable Medicines 
Facility for Malaria (AMFm) is an innovative 
financing mechanism intended to expand access 
to malaria medicines through public, private, and 
non-Governmental (NGO) mechanisms [4].  
AMFm strategies include subsidies to assure the 
cost-competitiveness of ACTs in the 
marketplace, and the utilization of ACTs in 
preference to less effective treatments [5].  A 
primary reason for the use of ACTs is the 
emergence of plasmodial strains that are 
resistant to older drugs such as chloroquine [6].  
Half of the world's population is at risk for 
malaria; 243 million new infections were 
estimated to have occurred in 2006 [7]. Malaria 
caused approximately 863 000 deaths in 2008 
[8].  About 91 % of malaria deaths in 2006 
occurred in Africa; 85 % of these were children 
under the age of five [9].  The most deadly 
infectious strain, Plasmodium falciparum (P. 
falciparum) is among the leading causes of death 
worldwide from a single infectious agent. Four 
major tactics utilized for malaria control are (1) 
the eradication of mosquito breeding grounds; (2) 
internal residual spraying; (3) the use of 
chemically-treated bed nets to prevent 
transmission; and (4) effective chemotherapy for 
infected individuals [10].   Effective 
chemotherapy for uncomplicated malaria is 
predominately based on the use of a semi-
synthetic derivative of artemisinin in combination 
with a synthetic malaria drug to reliably provide 
high rates of remission. The artemisinin-derived 
component of an ACT rapidly clears parasites 
from circulating blood plasma, but has a 
relatively short half-life (a few hours).  The 
synthetic component of an ACT has a long 
residence time in tissues (days, or even weeks), 
to prevent the re-emergence of symptomatic 
infection.  The WHO Essential Medicines List 
(EML) includes ACT combination therapies.  
Drug purchases by the AMFm and other NGOs 
are limited to suppliers who assure the quality of 
their products according to Strict Regulatory 
Authority (SRA) guidelines.  Good Manufacturing 
Practice (GMP) is required of all drug 
manufacturers.  Each product for every 
manufacturer is approved based upon the 
combination of a review of an appropriate 
regulatory dossier and an on-site inspection to 
assure the validated quality and consistency of 
production. SRAs include the World Health 
Organization’s Prequalification Program for 
medicines (WHO PQP) [11] and the US FDA 
[12]; both of these organizations draw very 
heavily from the concepts and documentation of 
the International Conference on Harmonization of 
Technical Requirements for the Registration of 
Pharmaceuticals for Human Use (ICH) [13] .  The 
QAMSA (Quality of Anti-malarials in Sub-
Saharan Africa) study found huge differences in 
the failure rates of malaria medicines which had 
been pre-qualified by the WHO PQP (4 %) 
versus those which were not SRA-approved (40 
%) [14].   
 
Regional (private sector) pharmaceutical 
companies exist in most African countries.  
Tanzania and Kenya are two East African 
countries with individual populations of 35 - 45 
million people.  Recent data indicates that twenty 
pharmaceutical manufacturing companies are 
operating in Kenya and another nine in Tanzania 
[15,16].  Only two African companies are known 
to be involved in the commercial cultivation, 
isolation and purification of artemisinin for ACTs 
production [17].  Most African pharmaceutical 
companies purchase Active Pharmaceutical 
Ingredients from India or China and prepare 
finished dosage forms for sale. No African 
companies currently manufacture their own APIs 
for ACTs on commercial scale. The Republic of 
South Africa is the only National Drug Regulatory 
Agency in Sub-Saharan Africa currently 
approved as an SRA.  The inspection and 
approval of companies in Sub-Saharan Africa to 
verify GMP status and Quality-Assurance, 
therefore, is carried out by SRAs external to the 
country of origin – largely the WHO PQP, PIC/S, 
and the US FDA.   
 
Our work in Africa is intended to (1) enable 
regional pharmaceutical companies to achieve 
SRA approval for medicines production; (2) to 
enable National Drug Regulatory Agencies to 
achieve SRA status; and (3) to eliminate 
counterfeit and substandard medicines.  We 
teach the principles of drug development, GMP 
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and quality-assurance for drug production and 
the preparation of Regulatory dossiers to 
pharmaceutical professionals and National Drug 
Regulators as a means of achieving these ends.  
Training takes place at the Saint Luke 
Foundation / Kilimanjaro School of Pharmacy 
(SLF/KSP) in Moshi, Tanzania.  Funding for this 
program has been partially subsidized to date 
(2012) by the United Nations Industrial 
Development Organization (UNIDO).  We have 
concluded that a priority means of expanding 
access to quality-assured medicines should be 
by raising the quality of local production and drug 
regulation in Africa to meet international 
standards, and to enable local producers to sell 
their products to GFATM and PEPFAR through 
their country Ministry of Health. The WHO-
recommends the use of ACTs for all patients who 
can tolerate them [18].  ACTs currently 
recommended for use in the treatment of 
uncomplicated malaria are artemether-
lumefantrine (ALU), artesunate-amodiaquine 
(ASAQ), artesunate-mefloquine (ASM), 
artesunate-sulfadoxine-pyrimethamine (ASSP) 
and dihydroartemisinin-piperaquine (DHAP). The 
combination of dihydroartemisinin + piperaquine 
in fixed-dose combination tablets containing 
50/135 mg or  100/270 mg of aretmisinin and PQ 
is a safe, well-tolerated, and highly effective 
treatment for P. falciparum malaria in Asia and 
Africa [19].   DHAP is a relatively recent ACT that 
is recommended for first-line treatment in 
Vietnam (2007) and is rapidly gaining in 
popularity in Africa because of its reliability, cost, 
and rapid onset of action.  DHAP manufactured 
by Sigma Tau was recently (2011) added to the 
WHO Model List of Essential Medicines [20]. 
 
The purpose of this work was to provide a robust, 
efficient synthesis of the malaria drug 





1H and 13C NMR spectra were recorded using 
Bruker spectrometer (400 MHz and 101 MHz) . 
1H NMR chemical shifts are reported in ppm 
using the deuterated solvent chloroform (CDCl3) 
or dimethylsulfoxide (DMSO, D6) as calibration 
standards (CDCl3: 7.27 ppm, DMSO: 2.49 ppm). 
The data are reported as follows: chemical shift, 
multiplicity (s = singlet; d = doublet; t = triplet; q = 
quartet; mult = multiplet), coupling constants 
(Hz), integration. 13C NMR chemical shifts are 
reported in ppm using the deuterated solvent 
CDCl3 (77.0 ppm) or DMSO, D6 (39.5 ppm) as 
calibration standard. 13C NMR was obtained with 
complete proton decoupling. DEPT-135, COSY, 
HETCOR recorded using Bruker spectrometer 
(400 MHz). 
 
Mass spectra (exact mass) recorded using 
LS/MS 1260 Series Infinity Agilent Technologies 
Analytical Instrument equipped with 6224 Time of 
Flight (TOF) LS/MS Spectrometer. HPLC was 
performed using 1200 Series Agilent 
Technologies Analytical Instrument equipped 
with a diode array UV detector. Melting points 
were obtained on an Electrothermal Mel-Temp 
apparatus and are uncorrected.  
 
Piperaquine phosphate (tetraphosphate salt) 
from Mangalam Chemical (India) was used as a 
reference standard.  4,7-Dichloroquinoline (DCQ; 
97 %), piperazine (97 %), 1,3-dibromopropane 
(99 %), ethyl acetate and 2-propanol (reagent 
grade) were purchased from Sigma-Aldrich 
Corporation and used as received.  Potassium 
carbonate and phosphoric acid (85 % aqueous 
H3PO4) were purchased from Mallinckrodt and 
used as received.  Water met the local 
requirements for potable water.    
 
Reverse-phase high-pressure liquid 
chromatography (HPLC) was carried out with 
1200 Series Agilent Technologies analytical 
instrument equipped with a diode array UV 
detector. HPLC was initially used to monitor 
reactions, analyze isolated products, and define 
the optimal range of processing conditions.  
Correlation between HPLC and thin-layer 
chromatography (TLC) demonstrated that TLC is 
adequate to monitor reactions in progress. 
 
The HPLC mobile phase (isocratic) used was 
80:20 acetonitrile:10 mM aqueous phosphate 
buffer adjusted to pH 6.9 with triethylamine.  A 
Zorbax Extend C18 column, 15 cm X 0.46 cm ID 
was used at a flow rate of 1 mL/min, with UV-
detection at a wavelength of 263 nM.  Injection 
volume for samples was 1 microliter.  This HPLC 
method was used to monitor both stages of the 
synthesis; this method is also suitable for 
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Figure 2: Route of synthesis for piperaquine phosphate 
   
 
Figure 3: Generation of toxic impurity (3) 
 





4,7-Dichloro-quinoline (DCQ), 4 2.41  
Step 1 Product, 1 2.55  
Piperaquine, 2 (free base) 4.12 
Dimeric impurity, 3 7.46 
 
Piperaquine is a well-known, commercial drug, 
spectra for its identification have been published 
[21].  Mass Spectra(exact mass) recorded using 
LS/MS 1260 Series Infinity Agilent Technologies 
facility while 13C and 1H NMR  spectra were 
recorded using Bruker spectrometer (400 MHz 
and 100 MHz) to confirm the identity of the 
compounds.  
 
Piperaquine is a member of the 4-aminoquinoline 
class of antimalarial compounds.  Although 
piperaquine is the sole example of a bis-(4-
aminoquinoline) drug that is widely approved for 
the treatment of malaria, quite a number of bis-
quinolines with powerful activity against malarial 
parasites are known[22].  Piperaquine and its 
anti-malarial activity were first disclosed by the 
pharmaceutical company Rhone-Poulenc in the 
1960s[23].  The synthesis is straightforward.  
Substitution of 4-haloquinolines by amine 
nucleophiles (Figure 2; Step One, using 4,7-
dichloroquinoline, 4) is well known; similar 
chemistry is used to prepare chloroquine, 
amodiaquine, and structurally-similar malaria 
drugs[24].  
The preparation of 1 from 4,7-dichloroquinoline 
(DCQ) requires the nucleophilic substitution of a 
piperazine nitrogen  for chloride on the quinoline 
ring.  This reaction is known to have a competing 
side reaction (Figure 3).  The step one product is 
more nucleophilic than piperazine itself, giving 
rise to a rapid, unwanted side reaction with DCQ 
that forms substantial amounts of the toxic, bis-
quinoline impurity 3. 
 
Previous publications have described the 
preparation of 1 [21,23,25,26].  Piperazine (a 
minimum of 3 mol eq) and DCQ are reacted in 2-
propanol (7-10 volumes w/v) at reflux, using 
potassium carbonate as a base  to neutralize the 
stoichiometric amount of hydrochloric acid that is 
generated during the displacement reaction.  An 
excess of piperazine is used to minimize the 
formation of the toxic impurity 3, although some 
of this impurity (typically 2 - 5) is most often 
observed.  Purifying 1 to remove impurity 3 is 
extremely inefficient.  Impurity 3 is generally 
removed by extraction into dichloromethane 
while the desired product is dissolved in aqueous 
acid.  For step two, previous procedures describe 
the reaction of 1 with 1-bromo-3-chloropropane 
or 1,3-dibromopropane in N,N-dimethyl-
formamide (DMF) or another polar, aprotic 
solvent using potassium carbonate as base.  
Water has also previously been used as a 
solvent in step two.  In a final operation, the free 
base of piperaquine is converted into the desired 
traphosphate salt by the slow addition of 
phosphoric acid to a suspension of the free base 
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Step One  
 
7-Chloro-4-(1-piperazinyl)-quinoline (1) 
Approximately 250 mL of 2-propanol was 
introduced into a round-bottom flask equipped 
with a stirring apparatus, heating mantle and 
reflux condenser.  4,7-Dichloroquinoline (100.0 g, 
0.50 mol) is added via a powder funnel with 
stirring.  The DCQ is observed to readily dissolve 
in the 2-propanol.  Piperazine (130.5 g, 1.51 mol, 
3.0 mol eq) is added as a solid through the 
powder funnel.  The stirred suspension is then 
heated to reflux, resulting in a golden-yellow 
solution.  The reaction is monitored by TLC for 
completion (approximately 5.5 h; 80:20:4 CHCl3: 
MeOH:AcOH, silica gel followed by Iodine 
visualization). When the reaction was vcomplete, 
the source of heat was removed and stirring 
continued for approximately 30 min. During this 
time a white precipitate (mixture of 1 and 
unreacted piperazine) was observed to form.  
Ethyl acetate (700 mL; 7 volumes w/v) was 
added to the stirred suspension over about 5 
minutes. Stirring was continued for an additional 
2 h to maximize the precipitation of unreacted 
piperazine from solution.  The suspension was 
filtered, the filter cake washed with approximately 
50 mL of ethyl acetate, and the combined ethyl 
acetate layers were washed with 2 x 350 mL of 
water.  These extractions removed remaining 
piperazine from the ethyl acetate layer and 2-
propanol.  The ethyl acetate layer was then 
concentrated by distillation under reduced 
pressure to approximately 40 % of its original 
volume and filtered to isolate Compound 1 as a 
white solid.  The crude Compound 1 was carried 
on to step two as a wet cake.  After drying to a 
constant weight, approximately 119 g of 1 was 
obtained (96 % yield corrected for the purity of 
DCQ and 1).  DCQ can be purchased with a 
purity of about 96.5 -98.0 % and the 4,5-
dichloroquinoline isomer is the major impurity 
present (1.0 - 2.5 %).  Compound 1 is typically 
isolated in a purity of > 99.0 % with small 
amounts of unreacted DCQ (NMT 0.20 %) and 
the 5-chloro isomer of 1 (NMT 0.20 %) present 
as indicated by HPLC analysis [21]. A white 
solid, mp: 112 - 114 °C.  1H NMR (DMSO-d6, 
400 MHz) δ: 8.66 (1H, d, J = 5.0 Hz, H-1), 7.95 
(1H, s, H-5), 7.49 (1H, d, J = 2.2 Hz, H-3), 7.47 
(1H, d, J = 2.2 Hz, H-4), 6.90 (1H, d, J = 5.0 Hz, 
H-2), 3.04 (4H, d, J = 5.1 Hz, H-6, H-6’), 2.95 
(4H, d, J = 5.3 Hz, H-7, H-7’); 13C NMR (DMSO-
d6, 100 MHz) δ: 157.3 (C4), 152.6 (C2), 150.1 
(C9), 133.9 (C7), 128.5 (C8), 126.5 (C6), 126.0 
(C5), 121.9 (C10), 109.6 (C3), 53.7 (C11), 46.0 
(C12).  Mass Spectrum (esi): 246(12%), 231(15), 
217(11), 207(28), 205(100%), 191(15), 177(55), 
169(18), 164(58). Elemental Analysis:  
Calculated: (C13H14N3Cl): C = 63.0%; H = 5.65%; 
N = 16.9%); Found: C = 63.08%; H = 5.63%; N = 
16.7%). 
 
Formation of impurity: 1,4-Bis-(4,7-
dichloroquinoline)piperazine (3) 
 A reaction vessel equipped with a stirring 
apparatus, heat source, and a reflux condenser 
was charged with 1 (3.90 g, 19.7 mmol), 15 % aq 
HCl (19.5 mL, approximately 5.0 volumes w/v) 
and piperazine (1.0 g, 11.8 mmol, 0.6 mol eq). 
The stirred suspension was then heated to reflux, 
resulting in a clear, yellow-orange solution. The 
reaction was monitored by TLC for completion 
(reaction time approximately 16 h). TLC (3:97 
EtOAc : Hexane; silica gel). When the reaction 
was complete, the source of heat was removed 
and stirring i continued for 30 min. Compound 3 
was isolated by filtration as a pink solid and dried 
to a constant weight of 2.70 g (70.1 % yield).  1H 
NMR (DMSO-d6, 400 MHz) δ: 8.76 (2H, d, J = 
6.8 Hz, H-1, H-1’), 8.25 (2H, s, H-5, H-5’), 8.15 
(2H, d, J = 2.0 Hz, H-3, H-3’), 7.71 and 7.69 (2H, 
dd, J = 2.0 Hz, H-4, H-4’), 7.20 (2H, J = 6.8 Hz, 
H-2, H-2’), 6.0 (8H, br s, 8 x H-6); 13C NMR 
(DMSO-d6, 100 MHz) δ: 171.5 (C4,C4’), 145.3 
(C2, C2’), 140.4 (C9, C9’), 138.9 (C7, C7’), 127.9 
(C8, C8’), 126.5 (C6, C6’), 120.3 (C5, C5’), 119.1 
(C10, C10’), 106.8 (C3, C3’); Mass Spectrum (esi) 
m/z 411(M+2; 60%), 409(100%), 246(15), 
231(20), 217(15), 205(90), 177(60), 164(52).  
Elemental Analysis:  Calculated: (C22H18N4Cl2): C 
= 64.48 %; H = 4.40 %; N = 13.68 %);  Found: C 





piperazinyl)propane; piperaquine free base 
A reaction vessel equipped with a stirring 
apparatus, heat source, and a reflux condenser 
was charged with 1 (67.5 g, 0.273 mol), 2-
propanol (170 mL, approximately 2.5 volumes 
w/v) and water (390 mL, 5.8 volumes w/v).  The 
stirred suspension was then charged with 
potassium carbonate (75.4 g, 0.55 mol, 2.0 mol 
eq) and 1,3-dibromopropane (24.8 g, 0.123 mol, 
0.46 mol eq). The stirred suspension was heated 
to reflux and monitored by TLC (80:20:4 
CHCl3:MeOH:AcOH on silica gel, with iodine 
visualization).  The reaction took approximately 6 
h to reach completion. The reaction mixture was 
stirred with cooling and maintained at ambient 
temperature for at least 1 h before isolation of the 
crude free base of piperaquine by filtration.  
Drying of the crude material to a constant weight 
gave an isolated yield of 62.4 g (94.8% yield). A 
yellowish-white solid, mp: 165 °C.1H NMR 
(DMSO-d6, 400 MHz) δ: 8.79 (1H, d, J = 5.0 Hz, 
H-1), 8.70 (1H, d, J = 5.0 Hz, H-1’), 8.16 (1H, d, J 
= 9.0 Hz, H-5), 8.04 (1H, d, J = 2.9 Hz, H-5’), 
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8.03 (1H, d, J = 3.6 Hz, H-3), 7.97 (1H, d, J = 2.0 
Hz, H-3’), 7.62 (2H, dddd, J = 2.0, 2.0, 2.0, 2.2 
Hz, H-4, H-4’), 7.16 (1H, d, J = 5.0 Hz, H-2), 
7.0 (1H, d, J = 5.0 Hz, H-1’), 3.50 (2H, s, H-9), 
3.10 (8H, d, J = 4.9 Hz, H-6, H-6’), 3.00 (4H, s, 
H-8, H-8’), 2.97 (8H, d, J = 4.7 Hz, H-7, H-7’); 13C 
NMR (DMSO-d6, 100 MHz) δ: 157.4 (C4, C4’), 
152.6 (C2, C2’), 150.0 (C9, C9’), 134.0 (C7, C7’), 
128.3 (C8, C8’), 126.6 (C6, C6’), 126.1 (C5, C5’), 
121.8 (C10, C10’), 109.7 (C3, C3’), 62.6 (C14), 53.5 
(C11, C11’), 45.8 (C12, C12’), 34.0 (C13), 25.8 (C13’); 
Mass Spectrum (esi) m/z 539(M+4; 10%), 
538(M+3; 25), 537(M+2; 65), 535(100%); 
290(35); 288(100); 260(30), 245(18), 217(15).  
Elemental Analysis: Calculated: (C29H32N6Cl2): C 
= 65.0 %; H = 6.03 %; N = 15.70 %); Found: C = 
64.89 %; H = 6.07 %; N = 15.71 %). 
 
Synthesis of Piperaquine tetraphospate 
A suitable reaction vessel was charged with the 
product from step two (62.4 g, 0.117 mol) and 
stirred as an ice-chilled suspension with 250 mL 
(4 volumes w/v) of water.  Aqueous, 85 % 
phosphoric acid (H3PO4, 27.1 mL, 0.47 mol, 4.0 
mol eq) was added over a minimum of 1 h, 
followed by warming to room temperature and 
stirring for another 2 h. The product was isolated 
by filtration and allowed to air dry to a constant 
weight.  The recovery of piperaquine as the 
corresponding tetrahydrate of the tetraphosphate 
salt (MW 999.56) was nearly quantitative (about 




One legal requirement for the granting of a 
patent is that the inventors disclose the best 
method of practicing the described invention.  
Using experimental details from existing patent 
filings [23, 25,26], we estimate that various 
processes disclosed for the production of 
piperaquine utilize somewhere between 32 and 
55 kg of organic solvent (w/v) per kilogram of 
product produced. The overall yield of 
piperaquine phosphate from DCQ for these 
processes seemed to be in the range of 52 – 65 
%.  In addition, dichloromethane, acetonitrile, 
and N,N-dimethylformamide are solvents used 
during processing.  These solvents present 
environmental or toxicological difficulties for use, 
handling, and disposal.  Each of these was also 
extremely difficult to recycle.  We have attempted 
to improve upon previous processes in the 
choice of solvent, volumes of solvent used, 
telescoping together of multiple operations, and 
overall yield.   
 
The reaction of DCQ with 3 mole equivalents of 
piperazine in 2.5 volumes (w/v) of 2-propanol at 
reflux yielded 1 in very high chemical yield (> 96 
% in solution as determined by HPLC analysis).  
Most notably, under these conditions impurity 3 
was either completely absent or generated at 
levels of not more than 0.2 % (HPLC analysis).  
When the chemical reaction to produce 1 was 
finished, ethyl acetate (5 volumes w/v) is added 
to the reaction and the resulting suspension was 
filtered to remove precipitated piperazine.  
Approximately 1.3 mole equivalents of piperazine 
was recovered by this filtration; recovered 
material has been recycled for use in making 
subsequent batches of piperaquine.  The ethyl 
acetate layer was then washed with water to 
remove residual piperazine, leaving 1 in the 
organic layer.  Ethyl acetate was partially 
removed by distillation (to about 2 volumes w/v 
vs. product) and compound 1 is isolated by 
filtration.  For step two, intermediate 1 is reacted 
with 1,3-dibromopropane using potassium 
carbonate as base in a mixed solvent of 2-
propanol : water (Figure 2).   
 
It is critical that the charge of 1,3-
dibromopropane be carefully controlled so that 1 
is present in a slight excess during step two.  
Excess 1,3-dibromopropane present in the 
reaction mixture gives rise to impurities that are 
difficult to remove from piperaquine by extraction 
or crystallization. The piperaquine free base was 
isolated in high yields by direct filtration from the 
reaction suspension at ambient temperature; 
some upgrading of the purity of material occurs 
at this stage as process impurities were removed 
into the aqueous 2-propanol reaction liquors.  
Piperaquine free base may be processed as a 
wet cake and was converted to the desired 
tetraphosphate salt by addition of phosphoric 
acid to an aqueous suspension of the wet cake.  
This process yielded piperaquine as the 
tetrahydrate form of its tetraphosphate salt in 92-
93% overall yield from DCQ, with none of the 
toxic impurity 3 present (< 0.03 %).  The 
technology employed is robust and seems 
appropriate for implementation in resource-
limited settings.  Minimal amounts of waste are 
generated during the process (roughly 8 kg/kg of 
API free base), of which about 60 % was directly 
recoverable by distillation of ethyl acetate as a 
single solvent.  The recovery and recycling of 
approximately 65 % of the excess, unreacted 
piperazine used in the process has also been 
successfully demonstrated.  Related substances 
in the final piperaquine tetraphosphate were all 
below 0.1 % as determined by HPLC analysis. 
 
DISCUSSION   
 
This article discloses an efficient, convenient 
synthesis of the API piperaquine tetraphosphate. 
The overall yield is approximately 92 – 93 %, 
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with very low levels of related substances (each 
individual impurity < 0.1 %). This process 
generates a limited amount of organic waste 
(about 8 kg/kg of product) of which roughly 60 % 
can be recycled by distillation as a single solvent 
(ethyl acetate).  
 
The direct reaction of DCQ with piperazine can 
be successfully carried out in a number of 
solvents (e.g., ethanol, 1- and 2-propanol, acetic 
acid, 1-butanol, N,N-dimethylformamide, N-
methylpyrrolidinone, dimethylsulfoxide, N,N-
dimethylacetamide, and water).  As discussed 
above, the generation of impurity 3 is the most 
important element to control at this stage.  Base 
(most often K2CO3) was added to these reactions 
by previous investigators, as one mole equivalent 
of hydrochloric acid is generated during 
processing.  Under these conditions, or using 2.5 
equivalents or less of piperazine, we observed 
the formation of several percent or more of 
impurity 3.  We initially attempted to use water as 
the solvent for this reaction.  DCQ is only very 
modestly soluble in water, but step one can be 
accomplished quite effectively in aqueous 
hydrochloric acid.  The reaction of DCQ with 3 
mole equivalents of piperazine in 4 volumes (w/v) 
of 9.25 % aqueous hydrochloric acid at reflux 
gives complete conversion to 1 (1-2 hours on 
200 g scale) which may be isolated as the 
corresponding hydrochloride salt.  HPLC analysis 
indicates that the chemical yield of this reaction 
is about 94 % with modest amounts of product 
remaining in the reaction liquors (85 % isolated 
yield).  Importantly, we noted that under these 
conditions impurity 3 could not be detected  in 
the reaction mixture by HPLC.  
 
 
Figure 4: 7-chloro-quinolin-4-ol 6 in Step one 
 
One drawback to the use of water for this 
reaction, however, was the need to separate 1 
from unreacted piperazine, as these were seen 
to co-crystallize from aqueous solutions as either 
the free base or hydrochloride salts (depending 
upon the presence of hydrochloric acid).  In 
addition, about 3-6% percent of an impurity 
(compound 6; Figure 4) was formed in aqueous 
solutions during step one.  Finally, practical 
problems made it inconvenient to recover 1 in the 
free base form that is required for step two of the 
synthesis.  We had previously noted, however, 
that carrying out step one in 2-propanol without 
added base significantly suppressed the 
production of unwanted dimer 3.  Apparently the 
impact of generating a full mole equivalent of 
hydrochloric acid during this reaction 
substantially decreases the rate of dimer 
formation by protonating the product and 
reducing its reactivity.  This effect was confirmed 
by carrying out step one in either water or 2-
propanol with modest amounts (1-3 mol eq) of 
hydrochloric acid present.  This modification 
produced essentially no impurity 3 as seen by 
HPLC analysis (0.00 - 0.20%) of the reaction 
mixture and isolated intermediate 1.  Although 
water is generally preferred for reactions based 
on “green chemistry” concepts, we found that a 
minimum of 2-propanol (2.5 volumes, w/v) was 
preferred for this reaction in order to conveniently 
separate compound 1 from piperazine and to 
isolate this intermediate in its free base form.  
Piperazine must be rigorously excluded from 
step two in order to avoid the formation of related 
process impurities.  The conditions described in 
this manuscript for the workup and isolation of 
step one provide an easier means of separating 
1 from piperazine than when water is the reaction 
solvent.   
 
One important factor in assuring successful 
chemical production is to develop a process that 
can be routinely reproduced by people who are 
not trained chemists. The synthesis described 
here was successfully replicated by twenty-three 
individuals attending the St Luke Foundation/ 
Kilimanjaro School of Pharmacy training course 
in Industrial Pharmacy and GMP drug production 
in August, 2011 in Moshi, Tanzania. The 
technology is simple and robust, and yields API 
that meets all requirements for processing 




We have successfully implemented an 
alternative, green-chemical synthesis of 
piperaquine tetraphosphate.  This synthesis is 
carried out in two chemical steps and an overall 
yield of about 92 – 93 %.  This synthesis 
generates approximately 8 kg of organic waste 
per kilogram of product produced.  Approximately 
60 % of this waste can be recovered and 
recycled in the form of crystalline piperazine and 
ethyl acetate.  HPLC analysis confirms that the 
piperaquine phosphate produced is very pure 
(related substances each not more than 0.1 % 
and total NMT 0.5 %).  The isolated product is 
obtained in the correct salt form and in sufficient 
purity for use in preparing artemisinin 
combination therapies.  This synthesis would 
seem to fit the requirements for utilization in a 
Fortunak et al 
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resource-limited setting for production of the API 
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